KLRS
Kalaris Therapeutics, Inc.
Key Financials
Net Income
$-43438000
↑ 26.1%
Operating Income
$-46152000
↑ 29.5%
Revenue
$165000
N/A
Total Assets
$121.7M
↑ 2.7%
Shareholders' Equity
$78.8M
↓ 30.4%
Total Liabilities
$42.9M
↑ 719.3%
EPS (Diluted)
$-2.85
↑ 75.7%
Cash & Equivalents
$98.1M
↓ 17.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/12/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| ARS | 4/24/2026 | View on SEC |
| DEFA14A | 4/24/2026 | View on SEC |
| DEF 14A | 4/24/2026 | View on SEC |
| EFFECT | 4/13/2026 | View on SEC |
| EFFECT | 4/13/2026 | View on SEC |
| 424B3 | 4/13/2026 | View on SEC |
| 424B3 | 4/13/2026 | View on SEC |
| 8-K | 4/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KLRS |
| Company Name | Kalaris Therapeutics, Inc. |
| CIK | 1754068 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-249-2727 |